Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Reply to Oude Lashof and Vogelaers.

Safdar N, Baddley J, Andes D.

Clin Infect Dis. 2013 May;56(10):1515-6. doi: 10.1093/cid/cit062. Epub 2013 Feb 5. No abstract available.

PMID:
23386636
2.

The end of an era in defining the optimal treatment of invasive candidiasis.

Clancy CJ, Nguyen MH.

Clin Infect Dis. 2012 Apr;54(8):1123-5. doi: 10.1093/cid/cis023. Epub 2012 Mar 12. No abstract available.

PMID:
22412062
3.

Does a patient-level quantitative review of randomized trials on the outcomes in candidemia and invasive candidiasis need to include all patients?

Oude Lashof AM, Vogelaers D.

Clin Infect Dis. 2013 May;56(10):1514-5. doi: 10.1093/cid/cit061. Epub 2013 Feb 5. No abstract available.

PMID:
23386635
4.

Selection bias in Andes et al.

Cisneros JM, Neth O, Pachón J.

Clin Infect Dis. 2012 Sep;55(6):893-4; author reply 894-5. doi: 10.1093/cid/cis524. Epub 2012 Jun 18. No abstract available.

PMID:
22711066
5.

Far-reaching conclusions based on weak and missing data.

Anaissie E, Nucci M.

Clin Infect Dis. 2012 Sep;55(6):890-3; author reply 894-5. doi: 10.1093/cid/cis521. Epub 2012 Jun 18. No abstract available.

PMID:
22711067
6.

Reply to Chow and Hurley.

Jaijakul S, Ostrosky-Zeichner L.

Clin Infect Dis. 2013 Feb;56(3):466-7. doi: 10.1093/cid/cis906. Epub 2012 Oct 22. No abstract available.

PMID:
23090934
7.

Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis.

Craver CW, Tarallo M, Roberts CS, Blanchette CM, Ernst FR.

Clin Ther. 2010 Dec;32(14):2467-77. doi: 10.1016/j.clinthera.2011.01.001.

PMID:
21353115
8.

Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.

Undre NA, Stevenson P, Freire A, Arrieta A.

Pediatr Infect Dis J. 2012 Jun;31(6):630-2. doi: 10.1097/INF.0b013e31824ab9b0.

PMID:
22301478
9.

Echinocandins--first line in invasive candidiasis: how strong is this 'strong' evidence?

Gonçalves-Pereira J, Póvoa P.

Crit Care. 2011;15(6):461; author reply 461. doi: 10.1186/cc10580. Epub 2011 Dec 15. No abstract available.

10.

Invasive candidiasis following liver transplantation and surgical complications.

Auzinger G.

Mycoses. 2011 Dec;54 Suppl 4:4-7. doi: 10.1111/j.1439-0507.2011.02135.x.

PMID:
22126522
11.

(1->3) β-D-glucan as a prognostic marker.

Chow H, Hurley JC.

Clin Infect Dis. 2013 Feb;56(3):466. doi: 10.1093/cid/cis903. Epub 2012 Oct 22. No abstract available.

PMID:
23090929
12.

Optimizing micafungin dosing in children.

Zhao W, Hope WW, Manzoni P, Jacqz-Aigrain E.

Pediatr Infect Dis J. 2012 Nov;31(11):1211-2; author reply 1212. doi: 10.1097/INF.0b013e3182624bac. No abstract available.

PMID:
23069801
13.

Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care.

Takesue Y, Oda S, Fujishima S, Mikamo H, Aikawa N.

J Infect Chemother. 2012 Aug;18(4):515-21. doi: 10.1007/s10156-012-0371-1. Epub 2012 Feb 23.

PMID:
22358542
14.

Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis.

Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L.

J Clin Microbiol. 2012 Jun;50(6):2104-6. doi: 10.1128/JCM.00773-12. Epub 2012 Mar 29.

15.

Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.

Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, Palazzi DL, Castagnola E, Halasa N, Velegraki A, Dvorak CC, Charkabarti A, Sung L, Danziger-Isakov L, Lachenauer C, Arrieta A, Knapp K, Abzug MJ, Ziebold C, Lehrnbecher T, Klingspor L, Warris A, Leckerman K, Martling T, Walsh TJ, Benjamin DK Jr, Zaoutis TE; International Pediatric Fungal Network.

Pediatr Infect Dis J. 2012 Dec;31(12):1252-7. doi: 10.1097/INF.0b013e3182737427.

PMID:
22982980
16.

[Candidemia and invasive candidiasis in the adult: clinical forms and treatment].

Cervera C.

Enferm Infecc Microbiol Clin. 2012 Oct;30(8):483-91. doi: 10.1016/j.eimc.2012.02.003. Epub 2012 Mar 28. Review. Spanish.

PMID:
22459688
17.

Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU.

Coyle EA.

J Pharm Pract. 2010 Feb;23(1):33-7. doi: 10.1177/0897190009356552. Review.

PMID:
21507791
18.

Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF.

Clin Microbiol Infect. 2012 Feb;18(2):E20-3. doi: 10.1111/j.1469-0691.2011.03712.x. Epub 2011 Nov 30.

19.

Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.

Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Bartlett K, Wasan KM.

Int J Pharm. 2012 Oct 15;436(1-2):318-23. doi: 10.1016/j.ijpharm.2012.06.062. Epub 2012 Jul 6.

PMID:
22772485
20.

Invasive candidiasis complicating renal transplantation.

Weerakkody RM, Heiyantuduwa DS, Sheriff MH.

Nephrology (Carlton). 2013 Feb;18(2):157. doi: 10.1111/j.1440-1797.2012.01623.x. No abstract available.

PMID:
23331956

Supplemental Content

Support Center